HDL quality, not quantity, contribute to the first sign of Alzheimer's disease in women

HDL particles vary in their size, composition and level of functioning. The team measured these features in the blood of 503 women from the Study of Women's Health Across the Nation (SWAN) HDL ancillary study. The researchers found that, over time, the number of larger HDL particles in the women's bodies increased -- and these larger particles, unfortunately, did not function as well as their smaller counterparts.

The researchers conducted repeated assessments of study participants' cognitive function from 2000 to 2016 and compared these data to changes in the women's HDL particles, composition and function as they aged.

"We were able to show that as early as midlife, women who have more of the smaller-sized particles and those whose particles' concentrations of phospholipids increased over the menopause transition are more likely to experience better episodic memory later in life," said Samar R. El Khoudary, Ph.D., M.P.H., professor of epidemiology at Pitt Public Health, adding that loss of working memory is the first sign of Alzheimer's disease.

Previously, El Khoudary's team has shown that health behaviors -- such as those included in the American Heart Association's (AHA) Life's Essential 8 -- work to improve the quality of HDL particles, for example by adding more of the phospholipid-rich particles in the bloodstream.

"That's the good news in this developing picture of brain health and the 'not-so-good-after-all' cholesterol," said El Khoudary. "Even though higher levels of HDL-C may not be protective as you get older, there are things you can do that might help, even as early as your 40s. The same, modifiable risk factors that the AHA is advocating for -- including physical activity, ideal body weight and quitting smoking -- can help you protect your brain, too."

Meiyuzhen Qi, Ph.D., post-doctoral researcher in the Department of Epidemiology at Pitt Public Health, is first author of this study. Additional coauthors include scientists from the University of Pennsylvania Perelman School of Medicine, Rush University Rush Medical Center, University of California Los Angeles David Geffen School of Medicine, Albert Einstein College of Medicine, University of Michigan School of Public Health and University of Massachusetts Medical School.